|
Originally published In Press as doi:10.1074/jbc.M604457200 on October 24, 2006
J. Biol. Chem., Vol. 282, Issue 1, 208-215, January 5, 2007
Cdc7 Is an Active Kinase in Human Cancer Cells Undergoing Replication Stress*
Pierluigi Tenca,
Deborah Brotherton1,
Alessia Montagnoli,
Sonia Rainoldi,
Clara Albanese, and
Corrado Santocanale2
From the
Department of Cell Biology, Nerviano Medical Sciences-Oncology, Via Pasteur 10, 20014 Nerviano, Italy
Cdc7 kinase promotes and regulates DNA replication in eukaryotic organisms. Multiple mechanisms modulating kinase activity in response to DNA replication stress have been reported, supporting the opposing notions that Cdc7 either plays an active role under these conditions or, conversely, is a final target inactivated by a checkpoint response. We have developed new immnunological reagents to study the properties of human Cdc7 kinase in cells challenged with the ribonucleotide reductase inhibitor hydroxyurea or with the DNA topoisomerase II inhibitor etoposide. We show that Cdc7·Dbf4 and Cdc7·Drf1 complexes are stable and active in multiple cell lines upon drug treatment, with Cdc7·Dbf4 accumulating on chromatin-enriched fractions. Cdc7 depletion by small interfering RNA in hydroxyurea and etoposide impairs hyper-phosphorylation of Mcm2 at specific Cdc7-dependent phosphorylation sites and drug-induced hyper-phosphorylation of chromatin-bound Mcm4. Furthermore, sustained inhibition of Cdc7 in the presence of these drugs increases cell death supporting the notion that the Cdc7 kinase plays a role in maintaining cell viability during replication stress.
Received for publication, May 10, 2006
, and in revised form, October 5, 2006.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1S5.
1 Current address: Chroma Therapeutics, 93 Milton Park, Abingdon OX14 5RY, United Kingdom.
2 To whom correspondence should be addressed. Tel.: 390331581145; Fax: 390331581374; E-mail: corrado.santocanale{at}nervianoms.com.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. J. Szyjka, J. G. Aparicio, C. J. Viggiani, S. Knott, W. Xu, S. Tavare, and O. M. Aparicio
Rad53 regulates replication fork restart after DNA damage in Saccharomyces cerevisiae
Genes & Dev.,
July 15, 2008;
22(14):
1906 - 1920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Nambiar, A. Mirmohammadsadegh, M. Hassan, R. Mota, A. Marini, A. Alaoui, A. Tannapfel, J. H. Hegemann, and U. R. Hengge
Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance
Carcinogenesis,
December 1, 2007;
28(12):
2501 - 2510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. P. Heffernan, K. Unsal-Kacmaz, A. N. Heinloth, D. A. Simpson, R. S. Paules, A. Sancar, M. Cordeiro-Stone, and W. K. Kaufmann
Cdc7-Dbf4 and the Human S Checkpoint Response to UVC
J. Biol. Chem.,
March 30, 2007;
282(13):
9458 - 9468.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|